|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/06/15 Acadia Pharmaceuticals Inc 10-Q 6/30/15 43:1.7M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 346K
2: EX-3.1 Articles of Incorporation/Organization or Bylaws HTML 25K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 18K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
26: R1 Document and Entity Information HTML 36K
18: R2 Condensed Consolidated Balance Sheets HTML 82K
24: R3 Condensed Consolidated Balance Sheets HTML 37K
(Parenthetical)
28: R4 Condensed Consolidated Statements of Operations HTML 41K
39: R5 Condensed Consolidated Statements of Operations HTML 21K
(Parenthetical)
19: R6 Condensed Consolidated Statements of Comprehensive HTML 32K
Loss
23: R7 Condensed Consolidated Statements of Cash Flows HTML 88K
17: R8 Basis of Presentation HTML 24K
13: R9 Net Loss Per Share HTML 25K
40: R10 Stock-Based Compensation HTML 21K
30: R11 Accrued Liabilities HTML 21K
29: R12 Investment Securities HTML 34K
34: R13 Fair Value Measurements HTML 39K
35: R14 Stockholders' Equity HTML 25K
33: R15 Commitments and Contingencies HTML 25K
36: R16 Recent Accounting Pronouncements HTML 20K
25: R17 Stock-Based Compensation (Policies) HTML 19K
27: R18 Net Loss Per Share (Tables) HTML 23K
32: R19 Accrued Liabilities (Tables) HTML 21K
43: R20 Investment Securities (Tables) HTML 29K
37: R21 Fair Value Measurements (Tables) HTML 33K
21: R22 Basis of Presentation - Additional Information HTML 18K
(Detail)
31: R23 Potential Common Shares Excluded in Calculating HTML 25K
Basic and Diluted Net Loss Per Common Share
(Detail)
22: R24 Stock-Based Compensation - Additional Information HTML 29K
(Detail)
12: R25 Accrued Liabilities (Detail) HTML 30K
38: R26 Investment Securities, All Classified as HTML 40K
Available-for-Sale (Detail)
41: R27 Fair Value Measurements - Additional Information HTML 19K
(Detail)
15: R28 Fair Value Measurements of Cash Equivalents and HTML 49K
Available-For-Sale Investment Securities (Detail)
14: R29 Stockholders' Equity - Additional Information HTML 32K
(Detail)
16: R30 Commitments and Contingencies - Additional HTML 27K
Information (Detail)
42: XML IDEA XML File -- Filing Summary XML 70K
11: EXCEL IDEA Workbook of Financial Reports XLSX 34K
5: EX-101.INS XBRL Instance -- acad-20150630 XML 389K
7: EX-101.CAL XBRL Calculations -- acad-20150630_cal XML 106K
8: EX-101.DEF XBRL Definitions -- acad-20150630_def XML 137K
9: EX-101.LAB XBRL Labels -- acad-20150630_lab XML 432K
10: EX-101.PRE XBRL Presentations -- acad-20150630_pre XML 283K
6: EX-101.SCH XBRL Schema -- acad-20150630 XSD 65K
20: ZIP XBRL Zipped Folder -- 0001193125-15-281018-xbrl Zip 51K
| EX-31.1 |
Exhibit 31.1
CERTIFICATION
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Stephen R. Davis, certify that:
1. I have reviewed this quarterly report on Form 10-Q of ACADIA Pharmaceuticals Inc.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| Date: August 6, 2015 | /S/ STEPHEN R. DAVIS | |||||
| Stephen R. Davis Interim Chief Executive Officer, Executive Vice President, Chief Financial Officer and Chief Business Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/6/15 | 8-K | ||
| For Period end: | 6/30/15 | |||
| List all Filings | ||||